Treatment with Intravenous Immune Globulin 10% in A Real-World Outpatient Setting

Richard Herrscher,Kevin Rosenbach, Quyen Luu, Dawn Kim-Romo,Lucinda Van Anglen

The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology（2023）

引用 0|浏览10

暂无评分

摘要

Intravenous immune globulin 10% liquid (IVIG 10%) is used in the treatment of primary immunodeficiency (PI). Originally approved in 2012 and then voluntarily withdrawn in 2016, IVIG 10% (BIVIGAM®) underwent manufacturing process improvements by a new manufacturer and was reintroduced to the US market in 2019. The purpose of this real-world study is to assess the tolerability of IVIG 10% infused in an outpatient setting.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要